샘플 요청 목록

 카트 문의
시장보고서
상품코드
1791471

항체 절편 시장

Antibody Fragments
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 176 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항체 절편 시장은 2030년까지 128억 달러에 이를 전망

2024년에 92억 달러로 추정되는 항체 절편 세계 시장은 2024-2030년간 CAGR 5.7%로 성장하여 2030년에는 128억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 단일클론항체는 CAGR6.7%를 나타내고, 분석 기간 종료시에는 77억 달러에 이를 것으로 예측됩니다. 다중클론항체 분야의 성장률은 분석 기간중 CAGR 4.4%로 추정됩니다.

미국 시장은 24억 달러로 추정, 중국은 CAGR 5.4%를 보일 것으로 예측

미국의 항체 절편 시장은 2024년에는 24억 달러에 이를 것으로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 5.4%로 2030년까지 20억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 5.2%와 4.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 4.5%를 보일 전망입니다.

항체 절편 시장 : 주요 동향과 성장 촉매 해명

항체 절편이 바이오의약품의 게임 체인저가 되는 이유는?

항체 절편은 전체 길이의 항체보다 높은 치료 효과, 높은 조직 투과성, 개선된 안전성 프로파일을 제공하여 바이오 의약품 산업에서 혁신적인 힘을 발휘하고 있습니다. 기존 단일클론항체와는 달리 항원 결합 부위를 유지하면서 Fc 영역을 제거하여 면역원성을 낮추고 종양, 염증성 질환, 신경질환에 대한 더 나은 타겟팅이 가능합니다. 분자 크기가 작아 생체 이용률이 향상되어 빠른 분포와 효율적인 세포 내 흡수가 중요한 용도에 적합합니다. 보다 효과적이고 저비용의 생물학적 제제에 대한 수요가 증가함에 따라 제약회사들은 새로운 단편 기반 치료법을 개발하기 위한 연구개발(R&:D)에 많은 투자를 하고 있습니다. 최근 재조합 DNA 기술과 합성 생물학 분야의 획기적인 발전은 항체 절편을 차세대 치료제의 필수적인 요소로 자리매김하면서 시장의 진화를 더욱 촉진하고 있습니다.

치료 용도 증가로 인해 시장 역학은 어떤 영향을 받고 있는가?

만성질환 및 자가면역질환의 유병률 증가와 표적 약물 전달의 발전은 항체 절편에 대한 수요를 촉진하고 있습니다. 이러한 생물학적 제제는 면역 체크포인트 억제 및 방사선 면역 요법을 강화하는 종양학 및 병원균의 보다 정확하고 강력한 중화를 제공하는 감염 치료에서 지지를 받고 있습니다. 안과 영역, 특히 노화성 황반변성(AMD)과 당뇨망막병증 치료에 적용하는 것도 시장의 급격한 확대에 기여하고 있습니다. 또한, 이중 특이성 및 삼중 특이성 항체 절편의 출현으로 여러 질병 경로를 동시에 표적으로 삼을 수 있게 되어 새로운 치료의 길이 열리고 있습니다. 대형 제약사들은 전략적 제휴를 맺고 이러한 첨단 바이오 치료제의 개발 및 경쟁 시장화를 가속화하고 있으며, 시장 경쟁과 혁신이 더욱 치열해지고 있습니다.

시장 확대에 있어 기술 혁신의 역할은?

항체 절편 제작 기술의 발전이 시장을 크게 형성하고 있습니다. 파지 디스플레이, 포유류 세포 발현 시스템, 박테리아 발효의 발전으로 생산 공정이 간소화되고 수율과 비용 효율성이 향상되었습니다. 차세대 염기서열 분석(NGS)과 인공지능(AI)을 활용한 신약개발은 고친화도 항체 절편의 신속한 식별과 최적화를 통해 신약 시장 출시 시간을 단축하고 있습니다. 또한, 흡입제제나 피하제제 등 비침습적 전달 메커니즘으로의 전환은 환자의 순응도를 높이고 시장 범위를 넓히고 있습니다. 규제 당국의 생물학적 제제에 대한 지원과 신속한 승인 경로도 혁신적인 항체 절편 기반 치료제의 상용화를 가속화하고 시장 전망을 더욱 강화하고 있습니다.

시장 성장을 가속하는 주요 요인은?

항체 절편 시장의 성장은 표적 생물학적 제제의 채택 증가, 면역 요법에 대한 연구 개발 투자 증가, 바이오프로세스 기술의 발전 등 여러 요인에 의해 주도되고 있습니다. 개인 맞춤형 의료에 대한 수요가 증가함에 따라 특정 환자군에 맞는 항체 절편의 개발이 더욱 가속화되고 있습니다. 또한, 개발 및 제조수탁기관(CDMO)의 확대로 대규모 생산이 용이해져 비용이 절감되고 상업화가 가속화되고 있습니다. 합성생물학 및 단백질 공학에 대한 관심이 높아지면서 개발 파이프라인이 강화되고 있으며, 특이성이 높고 강력한 치료제를 개발할 수 있게 되었습니다. 한편, 복잡한 질병의 확산이 증가하고 있고, 새로운 생물학적 제제의 승인을 촉진하는 규제 프레임워크가 진화하고 있다는 점이 시장 확대의 강력한 원동력이 되고 있습니다. 항체 절편 요법이 우수한 효능, 안전성, 환자 편의성을 지속적으로 입증함에 따라 다양한 치료 영역에서 채택이 급증하고 있으며, 향후 수년간 지속적인 시장 성장이 예상됩니다.

부문

특이성(단일클론항체, 다중클론항체);용도(면역 결핍 용도, 암 용도, 기타 용도)

조사 대상 기업 예

  • AbbVie Inc.
  • Absolute Antibody Ltd
  • Amgen Oncology
  • AstraZeneca PLC
  • Axplora Group GmbH
  • Creative Biolabs
  • Jackson ImmunoResearch Inc.
  • Lonza Group AG
  • Sanofi SA
  • Sino Biological, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Xpress Biologics

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.08.20

Global Antibody Fragments Market to Reach US$12.8 Billion by 2030

The global market for Antibody Fragments estimated at US$9.2 Billion in the year 2024, is expected to reach US$12.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the Polyclonal Antibodies segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 5.4% CAGR

The Antibody Fragments market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Antibody Fragments Market: Unveiling Key Trends & Growth Catalysts

What Makes Antibody Fragments a Game-Changer in Biopharmaceuticals?

Antibody fragments are emerging as a revolutionary force in the biopharmaceutical landscape, offering enhanced therapeutic efficacy, greater tissue penetration, and improved safety profiles over full-length antibodies. Unlike conventional monoclonal antibodies, these fragments retain antigen-binding sites while eliminating the Fc region, reducing immunogenicity and enabling better targeting of tumors, inflammatory diseases, and neurological disorders. Their smaller molecular size enhances bioavailability, making them ideal for applications where rapid distribution and efficient cellular uptake are critical. With increasing demand for more effective, lower-cost biologics, pharmaceutical companies are investing heavily in research and development (R&D) to create novel fragment-based therapies. Recent breakthroughs in recombinant DNA technology and synthetic biology are further propelling the market’s evolution, positioning antibody fragments as an essential component in next-generation therapeutics.

How Are Market Dynamics Influenced by Rising Therapeutic Applications?

The increasing prevalence of chronic and autoimmune diseases, coupled with advancements in targeted drug delivery, is fueling the demand for antibody fragments. These biologics are gaining traction in oncology, where they enhance immune checkpoint inhibition and radioimmunotherapy, as well as in infectious disease treatment, where they provide more precise and potent neutralization of pathogens. Ophthalmic applications, particularly in the treatment of age-related macular degeneration (AMD) and diabetic retinopathy, have also contributed to a surge in market expansion. Furthermore, the emergence of bispecific and trispecific antibody fragments is creating new therapeutic avenues by enabling simultaneous targeting of multiple disease pathways. Major pharmaceutical players are forming strategic alliances to accelerate the development and commercialization of these advanced biotherapeutics, further intensifying market competition and innovation.

What Role Does Technological Innovation Play in Market Expansion?

The evolution of antibody fragment production technologies is significantly shaping the market. Advances in phage display, mammalian cell expression systems, and bacterial fermentation have streamlined the manufacturing process, leading to higher yields and cost-efficiency. The adoption of next-generation sequencing (NGS) and artificial intelligence (AI) in drug discovery has enabled faster identification and optimization of high-affinity antibody fragments, reducing the time to market for novel therapies. Additionally, the shift toward non-invasive delivery mechanisms, such as inhalable and subcutaneous formulations, is enhancing patient compliance and broadening the market reach. Regulatory support and expedited approval pathways for biologics are also accelerating the commercialization of innovative antibody fragment-based treatments, further strengthening market prospects.

What Are the Key Drivers Fueling Market Growth?

The growth in the antibody fragments market is driven by several factors, including the increasing adoption of targeted biologics, rising R&D investments in immunotherapy, and advancements in bioprocessing technologies. The surging demand for personalized medicine has further catalyzed the development of antibody fragments tailored to specific patient populations. Additionally, the expansion of contract development and manufacturing organizations (CDMOs) is facilitating large-scale production, reducing costs, and accelerating commercialization. Growing interest in synthetic biology and protein engineering is enhancing the development pipeline, allowing for the creation of highly specific and potent therapeutic agents. Meanwhile, the rising prevalence of complex diseases, combined with evolving regulatory frameworks that encourage the approval of novel biologics, is providing a strong impetus for market expansion. As antibody fragment therapies continue to demonstrate superior efficacy, safety, and patient convenience, their adoption is expected to surge across diverse therapeutic domains, driving sustained market growth in the years to come.

SCOPE OF STUDY:

The report analyzes the Antibody Fragments market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Specificity (Monoclonal Antibodies, Polyclonal Antibodies); Application (Immunodeficiency Application, Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Absolute Antibody Ltd
  • Amgen Oncology
  • AstraZeneca PLC
  • Axplora Group GmbH
  • Creative Biolabs
  • Jackson ImmunoResearch Inc.
  • Lonza Group AG
  • Sanofi SA
  • Sino Biological, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Xpress Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antibody Fragments - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Antibody Fragments in Targeted Cancer and Autoimmune Therapies
    • Growth in Next-Generation Antibody Engineering for Improved Efficacy
    • Expansion of Biopharmaceutical Applications for Single-Domain Antibodies (sdAbs)
    • Increasing Use of Antibody Fragments in Drug Delivery and Imaging Applications
    • Surge in Demand for Bispecific and Multispecific Antibody Fragments
    • Advancements in Phage Display Technology for Antibody Fragment Discovery
    • Increasing Investments in AI-Driven Antibody Fragment Development
    • Expansion of Contract Research and Manufacturing Services for Antibody Fragments
    • Growing Role of Antibody Fragments in Cell and Gene Therapy Applications
    • Rising Focus on Fully Human and Recombinant Antibody Fragments for Therapeutics
    • Surge in Demand for Antibody Fragments in Biosensors and Diagnostic Platforms
    • Increasing Strategic Partnerships for Rapid Commercialization of Antibody Fragments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Fragments Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Fragments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Fragments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Fragments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polyclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polyclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polyclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunodeficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunodeficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunodeficiency Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antibody Fragments by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antibody Fragments by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Antibody Fragments by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of World 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제